Reprint of: Back to the Future! The Evolving Role of Maintenance Therapy after Hematopoietic Stem Cell Transplantation
作者： Christopher S. Hourigan , Philip McCarthy , Marcos de Lima
DOI: 10.1016/J.BBMT.2014.01.005
关键词: Minimal residual disease 、 Intensive care medicine 、 Allogeneic transplantation 、 Medicine 、 Transplantation 、 Hematopoietic stem cell transplantation 、 Context (language use) 、 Maintenance therapy 、 Autologous transplantation 、 Immunology 、 Transplantation Conditioning 、 Hematology
摘要: Relapse is a devastating event for patients with hematologic cancers treated hematopoietic stem cell transplantation. In most situations, relapse treatment options are limited. Maintenance therapy offers the possibility of delaying or avoiding disease recurrence, but its role remains unclear in conditions that we treat Here, Dr. Hourigan presents an overview minimal residual (MRD) measurement malignancies and applicability MRD-based post-transplantation interventions. McCarthy reviews current knowledge maintenance autologous transplantation context, emphasis on immunologic interventions immune modulation strategies designed to prevent relapse. de Lima discusses lines investigation recurrence prevention after allogeneic transplantation, focusing acute myeloid leukemia myelodysplastic syndrome.
core.ac.uk
bbmt.org
elsevier.com参考文章(108)
Gesine Bug, Andreas Burchert, Kroeger Nicolaus, Sabine Huenecke, Ulrich Duenzinger, Andrea Wolf, Peter Bader, Hubert Serve, Oliver G Ottmann, None, Post-Transplant Maintenance With The Deacetylase Inhibitor Panobinostat In Patients With High-Risk AML Or MDS: Results Of The Phase I Part Of The Panobest Trial Blood. ,vol. 122, pp. 3315- 3315 ,(2013) , 10.1182/BLOOD.V122.21.3315.3315
Michael Rytting, Lisa Triche, Deborah Thomas, Susan O'Brien, Hagop Kantarjian, Initial experience with CMC-544 (inotuzumab ozogamicin) in pediatric patients with relapsed B-cell acute lymphoblastic leukemia. Pediatric Blood & Cancer. ,vol. 61, pp. 369- 372 ,(2014) , 10.1002/PBC.24721
Carol O'Hear, Hiroto Inaba, Stanley Pounds, Lei Shi, Gary Dahl, W. Paul Bowman, Jeffrey W. Taub, Ching-Hon Pui, Raul C. Ribeiro, Elaine Coustan-Smith, Dario Campana, Jeffrey E. Rubnitz, Gemtuzumab ozogamicin can reduce minimal residual disease in patients with childhood acute myeloid leukemia. Cancer. ,vol. 119, pp. 4036- 4043 ,(2013) , 10.1002/CNCR.28334
Marcos De Lima, Sergio Giralt, Peter F Thall, Leandro de Padua Silva, Roy B Jones, Krishna Komanduri, Thomas M Braun, Hoang Q Nguyen, Richard Champlin, Guillermo Garcia‐Manero, None, Maintenance therapy with low-dose azacitidine after allogeneic hematopoietic stem cell transplantation for recurrent acute myelogenous leukemia or myelodysplastic syndrome: a dose and schedule finding study. Cancer. ,vol. 116, pp. 5420- 5431 ,(2010) , 10.1002/CNCR.25500
Philip L. McCarthy, Part I: The Role of Maintenance Therapy in Patients With Multiple Myeloma Undergoing Autologous Hematopoietic Stem Cell Transplantation Journal of The National Comprehensive Cancer Network. ,vol. 11, pp. 35- 42 ,(2013) , 10.6004/JNCCN.2013.0006
Jerald P. Radich, Monitoring response to tyrosine kinase inhibitor therapy, mutational analysis, and new treatment options in chronic myelogenous leukemia. Journal of The National Comprehensive Cancer Network. ,vol. 11, pp. 663- 666 ,(2013) , 10.6004/JNCCN.2013.0196
Margaret R. O’Donnell, Martin S. Tallman, Camille N. Abboud, Jessica K. Altman, Frederick R. Appelbaum, Daniel A. Arber, Eyal Attar, Uma Borate, Steven E. Coutre, Lloyd E. Damon, Jeffrey Lancet, Lori J. Maness, Guido Marcucci, Michael G. Martin, Michael M. Millenson, Joseph O. Moore, Farhad Ravandi, Paul J. Shami, B. Douglas Smith, Richard M. Stone, Stephen A. Strickland, Eunice S. Wang, Kristina M. Gregory, Maoko Naganuma, Acute myeloid leukemia, version 2.2013 featured updates to the NCCN guidelines Journal of The National Comprehensive Cancer Network. ,vol. 11, pp. 1047- 1055 ,(2013) , 10.6004/JNCCN.2013.0127
Mervi Putkonen, Veli Kairisto, Vesa Juvonen, Tarja-Terttu Pelliniemi, Auvo Rauhala, Maija Itälä-Remes, Kari Remes, Depth of response assessed by quantitative ASO-PCR predicts the outcome after stem cell transplantation in multiple myeloma. European Journal of Haematology. ,vol. 85, pp. 416- 423 ,(2010) , 10.1111/J.1600-0609.2010.01510.X
Jerald P. Radich, Andrew D. Zelenetz, Wing C. Chan, Carlo M. Croce, Myron S. Czuczman, Harry P. Erba, Sandra J. Horning, Jane Houldsworth, B. Douglas Smith, David S. Snyder, Hema M. Sundar, Meir Wetzler, Jane N. Winter, NCCN task force report: molecular markers in leukemias and lymphomas. Journal of The National Comprehensive Cancer Network. ,vol. 7, ,(2009) , 10.6004/JNCCN.2009.0077
A. Keith Stewart, Robert Vescio, Gary Schiller, Oscar Ballester, Stephen Noga, Hope Rugo, Cesar Freytes, Edward Stadtmauer, Stefano Tarantolo, Firoozeh Sahebi, Pat Stiff, Jacinta Meharchard, Robert Schlossman, Randy Brown, Heather Tully, Mark Benyunes, Cindy Jacobs, Ronald Berenson, Michael White, John DiPersio, Kenneth C. Anderson, James Berenson, Purging of Autologous Peripheral-Blood Stem Cells Using CD34 Selection Does Not Improve Overall or Progression-Free Survival After High-Dose Chemotherapy for Multiple Myeloma: Results of a Multicenter Randomized Controlled Trial Journal of Clinical Oncology. ,vol. 19, pp. 3771- 3779 ,(2001) , 10.1200/JCO.2001.19.17.3771